NASDAQ:OPTR - Optimer Pharmaceuticals Stock Price, Price Target & More

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Optimer Pharmaceuticals (NASDAQ:OPTR)

Optimer Pharmaceuticals logoOptimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on developing and commercializing hospital specialty products. The Company's development is focused on products that treat gastrointestinal infections and related diseases. Its two products OPT-822/821 and CEM-101 (OP-1068) are in clinical development. Optimer's products include Fidaxomicin and Solithromycin under anti-infectives, and OPT-822/821 under other therapeutic areas. In January 2011, its majority owned subsidiary, Optimer Biotechnology, Inc. (OBI) conducted a Phase 2/3 clinical, trial to evaluate OPT-822/821for the treatment of metastatic breast cancer. On May 27, 2011, the United States Food and Drug Administration (FDA) approved DIFICID(fidaxomicin) tablets, its antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). In October 2013, Cubist Pharmaceuticals, Inc announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.

Receive OPTR News and Ratings via Email

Sign-up to receive the latest news and ratings for OPTR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
SymbolNASDAQ:OPTR
CUSIP68401H10
Phone+1-201-3338819

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

How to Become a New Pot Stock Millionaire

Optimer Pharmaceuticals (NASDAQ:OPTR) Frequently Asked Questions

What is Optimer Pharmaceuticals' stock symbol?

Optimer Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPTR."

Who are some of Optimer Pharmaceuticals' key competitors?

Has Optimer Pharmaceuticals been receiving favorable news coverage?

News coverage about OPTR stock has trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Optimer Pharmaceuticals earned a news impact score of 0.14 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 47.59 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Optimer Pharmaceuticals?

Shares of OPTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Optimer Pharmaceuticals?

Optimer Pharmaceuticals' mailing address is 101 Hudson St Ste 3501, JERSEY CITY, NJ 07302-3915, United States. The biopharmaceutical company can be reached via phone at +1-201-3338819.


MarketBeat Community Rating for Optimer Pharmaceuticals (OPTR)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  144 (Vote Outperform)
Underperform Votes:  76 (Vote Underperform)
Total Votes:  220
MarketBeat's community ratings are surveys of what our community members think about Optimer Pharmaceuticals and other stocks. Vote "Outperform" if you believe OPTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPTR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Optimer Pharmaceuticals (NASDAQ:OPTR) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 4/23/2016 forward)

Earnings

Optimer Pharmaceuticals (NASDAQ:OPTR) Earnings History and Estimates Chart

Earnings by Quarter for Optimer Pharmaceuticals (NASDAQ:OPTR)

Optimer Pharmaceuticals (NASDAQ OPTR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2013Q2 2013($0.62)($0.55)$21.31 million$20.10 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.46)($0.65)$21.09 million$19.43 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.57)$0.02$18.05 million$19.50 millionViewN/AView Earnings Details
11/1/2012Q312($0.63)($0.56)$16.03 million$17.89 millionViewN/AView Earnings Details
7/31/2012($0.07)($0.01)ViewN/AView Earnings Details
5/10/2012($0.40)($0.23)ViewN/AView Earnings Details
3/7/2012$0.51$0.29ViewN/AView Earnings Details
11/3/2011($0.51)($0.57)ViewN/AView Earnings Details
8/4/2011($0.39)($0.52)ViewN/AView Earnings Details
5/5/2011($0.30)$1.04ViewN/AView Earnings Details
3/10/2011($0.33)($0.31)ViewN/AView Earnings Details
11/2/2010Q3 2010($0.29)($0.31)ViewN/AView Earnings Details
8/4/2010Q2 2010($0.30)($0.27)ViewN/AView Earnings Details
5/6/2010Q1 2010($0.41)($0.39)ViewN/AView Earnings Details
3/11/2010Q4 2009($0.34)($0.29)ViewN/AView Earnings Details
11/3/2009Q3 2009($0.36)($0.28)ViewN/AView Earnings Details
8/5/2009Q2 2009($0.33)($0.37)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.32)($0.36)ViewN/AView Earnings Details
3/11/2009Q4 2008($0.32)($0.35)ViewN/AView Earnings Details
11/5/2008Q3 2008($0.28)($0.31)ViewN/AView Earnings Details
8/6/2008Q2 2008($0.30)($0.29)ViewN/AView Earnings Details
5/7/2008Q1 2008($0.28)($0.29)ViewN/AView Earnings Details
3/26/2008Q4 2007($0.30)($0.27)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Optimer Pharmaceuticals (NASDAQ:OPTR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Optimer Pharmaceuticals (NASDAQ OPTR) Insider Trading and Institutional Ownership History

Insider Trading History for Optimer Pharmaceuticals (NASDAQ:OPTR)

Optimer Pharmaceuticals (NASDAQ OPTR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/8/2013Pedro LichtingerCEOSell148,000$14.69$2,174,120.00View SEC Filing  
11/8/2012Pedro LichtingerCEOBuy11,000$9.08$99,880.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Optimer Pharmaceuticals (NASDAQ OPTR) News Headlines

Source:
DateHeadline
Financial Comparison: Syndax Pharmaceuticals (SNDX) and Optimer Pharmaceuticals (OPTR)Financial Comparison: Syndax Pharmaceuticals (SNDX) and Optimer Pharmaceuticals (OPTR)
www.americanbankingnews.com - December 23 at 5:24 PM
Shire PLC (SHPG) versus Optimer Pharmaceuticals (OPTR) Financial ReviewShire PLC (SHPG) versus Optimer Pharmaceuticals (OPTR) Financial Review
www.americanbankingnews.com - September 19 at 8:10 PM
Financial Contrast: Optimer Pharmaceuticals (OPTR) versus Collegium Pharmaceutical (COLL)Financial Contrast: Optimer Pharmaceuticals (OPTR) versus Collegium Pharmaceutical (COLL)
www.americanbankingnews.com - September 18 at 4:28 AM

SEC Filings

Optimer Pharmaceuticals (NASDAQ:OPTR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Optimer Pharmaceuticals (NASDAQ:OPTR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Optimer Pharmaceuticals (NASDAQ OPTR) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.